Peptide News Digest

#Hypothalamic Obesity

3 stories

Hypothalamic obesity is severe, rapid, and largely uncontrolled weight gain caused by damage or dysfunction in the hypothalamic regions that regulate hunger and energy balance, particularly the MC4R signaling pathway. The condition takes two forms. Acquired hypothalamic obesity follows surgery, radiation, or trauma involving the hypothalamus, most commonly after craniopharyngioma resection in children. Genetic hypothalamic obesity arises from monogenic defects in POMC, PCSK1, LEPR, or MC4R itself.

In either form, patients gain weight at rates that exceed normal physiology, do not respond to diet or exercise, and historically had no targeted treatment options. Bariatric surgery has poor outcomes in this population; conventional appetite suppressants are mostly ineffective.

The field changed in 2020 when the FDA approved Rhythm Pharmaceuticals' setmelanotide (IMCIVREE) for POMC, PCSK1, and LEPR deficiency obesity. The label expanded to Bardet-Biedl Syndrome in 2022 and acquired hypothalamic obesity in March 2026 after the Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks. A 2.5-year long-term extension presented at ENDO 2026 (Christian Roth, Seattle Children's) reported -18.9% mean BMI reduction across all 11 participants, with sustained efficacy. Rhythm's next-generation MC4R agonist bivamelagon is now advancing.

Stories here cover hypothalamic obesity trial readouts, real-world data, and the targeted-therapy pipeline. See [[setmelanotide]], [[mc4r]], and [[rhythm-pharmaceuticals]] for adjacent threads.

Clinical Trials · View digest

Rhythm Pharmaceuticals Presents Setmelanotide ENDO 2026 Data Across Three Rare-Disease Indications: Acquired Hypothalamic Obesity 2.5-Year LTE, Prader-Willi Syndrome Phase 2 Interim, and Bardet-Biedl Syndrome Real-World

Rhythm Pharmaceuticals (Nasdaq: RYTM) presented seven setmelanotide abstracts at ENDO 2026 covering three rare-disease patient populations. Christian Roth (Seattle Children's) reported 2.5-year Phase 2 + long-term extension data in acquired hypothalamic obesity showing -18.9% mean BMI reduction across all 11 participants. The PWS interim Phase 2 (June 13) reported across 17 patients (10 adult, 7 pediatric) showed 3.11% mean BMI reduction in adults and 3.00% in pediatric patients, with 8 of 10 baseline-hyperphagic patients hitting a 7-point HQ-CT reduction, and 4.19% fat-mass loss with 0.74% lean-mass gain across 16 DEXA evaluations. Two BBS late-breaking posters from Caroline Huber covered real-world hyperphagia and healthcare-utilization outcomes from the 6-month RESTORE study. All three indications reinforce the MC4R-agonist rationale for Phase 3.

Clinical Trials · View digest

Rhythm Q1 2026: IMCIVREE Net Revenue $60.1M (+59% YoY) on Hypothalamic Obesity Launch — EMANATE Phase 3 Misses in All Four MC4R Substudies

Rhythm Pharmaceuticals reported Q1 2026 results May 5: setmelanotide (IMCIVREE) net product revenue of $60.1M, up from $37.7M a year earlier ($36.9M US, $23.2M ex-US), driven by 150+ new US start forms in acquired hypothalamic obesity following the FDA approval and the EU Marketing Authorization for the same indication; Japan's PMDA accepted the NDA for review. The MC4R-agonist peptide is the only commercial therapy for hypothalamic obesity. Offsetting the topline beat: the Phase 3 EMANATE trial in genetically caused MC4R-pathway diseases failed its primary endpoint in all four independent substudies, narrowing the indication-expansion runway. Net loss was $56.7M; cash $340.6M for 24+ months runway.